Wave Life Sciences Ltd Market Cap ($690.72 Million)
Market Cap & Net Worth: Wave Life Sciences Ltd (WVE)
Wave Life Sciences Ltd market cap. Wave Life Sciences Ltd (NASDAQ:WVE) has a market capitalization of $690.72 Million ($690.72 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10266 globally and #2779 in its home market, demonstrating a 7.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wave Life Sciences Ltd's stock price $3.59 by its total outstanding shares 192402202 (192.40 Million).
Wave Life Sciences Ltd Market Cap History (2015–2026)
Wave Life Sciences Ltd market cap history from 2015 to 2026. Data shows change from $3.07 Billion to $690.72 Million (-12.73% CAGR). Check WVE live share price for real-time trading data and today's change.
Index Memberships
Wave Life Sciences Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #290 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #1072 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.04% | #171 of 263 |
Weight: Wave Life Sciences Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Wave Life Sciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wave Life Sciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Wave Life Sciences Ltd (WVE) cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
76.55x
Wave Life Sciences Ltd's market cap is 76.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $5.03 Billion | $1.49 Million | -$55.40 Million | 3388.09x | N/A |
| 2017 | $6.75 Billion | $3.70 Million | -$102.03 Million | 1823.25x | N/A |
| 2018 | $8.09 Billion | $14.41 Million | -$146.65 Million | 561.16x | N/A |
| 2019 | $1.54 Billion | $15.98 Million | -$193.64 Million | 96.48x | N/A |
| 2020 | $1.51 Billion | $20.08 Million | -$149.91 Million | 75.42x | N/A |
| 2021 | $604.14 Million | $40.96 Million | -$122.25 Million | 14.75x | N/A |
| 2022 | $1.35 Billion | $3.65 Million | -$161.82 Million | 369.09x | N/A |
| 2023 | $971.63 Million | $113.31 Million | -$57.51 Million | 8.58x | N/A |
| 2024 | $2.38 Billion | $108.30 Million | -$97.01 Million | 21.98x | N/A |
| 2025 | $3.27 Billion | $42.73 Million | -$204.38 Million | 76.55x | N/A |
Competitor Companies of WVE by Market Capitalization
Companies near Wave Life Sciences Ltd in the global market cap rankings as of October 31, 2026. See WVE net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Wave Life Sciences Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Wave Life Sciences Ltd (2015–2026)
Market capitalization of Wave Life Sciences Ltd from 2015 to today. Between 2015 and today, Wave Life Sciences Ltd's market cap moved from $3.07 Billion to $ 690.72 Million, with a yearly change of -12.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $690.72 Million | -78.88% |
| 2025 | $3.27 Billion | +37.43% |
| 2024 | $2.38 Billion | +144.95% |
| 2023 | $971.63 Million | -27.86% |
| 2022 | $1.35 Billion | +122.93% |
| 2021 | $604.14 Million | -60.10% |
| 2020 | $1.51 Billion | -1.81% |
| 2019 | $1.54 Billion | -80.93% |
| 2018 | $8.09 Billion | +19.77% |
| 2017 | $6.75 Billion | +34.23% |
| 2016 | $5.03 Billion | +63.95% |
| 2015 | $3.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Wave Life Sciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $690.72 Million USD |
| MoneyControl | $690.72 Million USD |
| MarketWatch | $690.72 Million USD |
| marketcap.company | $690.72 Million USD |
| Reuters | $690.72 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more